Edgewise Therapeutics vs Ionis Pharmaceuticals
Edgewise Therapeutics (EWTX), health care, and Ionis Pharmaceuticals (IONS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Edgewise Therapeutics is worth $4.6B on the stock market and Ionis Pharmaceuticals $4.5B: Edgewise Therapeutics is valued at 3% more. Over the past year Edgewise Therapeutics's share price has moved +97.1% and Ionis Pharmaceuticals's -62.4%.
Key facts
- Edgewise Therapeutics market value
- $4.6B
- Ionis Pharmaceuticals market value
- $4.5B
- Edgewise Therapeutics P/E
- 5.0
- Ionis Pharmaceuticals revenue
- $943.7MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Edgewise Therapeutics | Ionis Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.6Bhigher | $4.5Blower |
| Revenue | — | $943.7M |
| Earnings | -$167.8Mhigher | -$381.4Mlower |
| Employees | 133lower | 1,485higher |
| Total assets | $552.6Mlower | $3.5Bhigher |
| Valuation | ||
| P/E | 5.0 | — |
| P/S | — | 4.8 |
| P/B | 2.8lower | 11.4higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | -40.4% |
| Balance sheet | ||
| Net assets | $522.3Mhigher | $489.1Mlower |
| Total liabilities | $30.3Mlower | $3Bhigher |
| Total debt | — | $1.8B |
| Cash on hand | $61.1Mlower | $372.3Mhigher |
| Price change | ||
| Today | -3.75%lower | -3.75%higher |
| 1 year | +97.1%higher | -62.4%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Julian and Felix Baker0.8% / 0.8%
Edgewise Therapeutics only (1)
- Peter Kolchinsky3.0%
Ionis Pharmaceuticals only (3)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Edgewise Therapeutics / Ionis Pharmaceuticals). Who owns EWTX · Who owns IONS
More on Edgewise Therapeutics
Further comparisons
Edgewise Therapeutics against its closest peers
Ionis Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Edgewise Therapeutics or Ionis Pharmaceuticals?
By market value, Edgewise Therapeutics is the larger: $4.6B against $4.5B for Ionis Pharmaceuticals.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Edgewise Therapeutics and Ionis Pharmaceuticals?
In their latest 13F filings, Julian and Felix Baker holds both.
Cite this page
Funkfolio, “Edgewise Therapeutics vs Ionis Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/ewtx-vs-ions
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.